Division of Basic Medical Research FY2018 List of Projects - Research Program on Hepatitis
Program for Basic and Clinical Research on Hepatitis
First Year | Final Year | Principal Investigator | Affiliation | Project Title | |
---|---|---|---|---|---|
FY2016 | FY2018 | Yasuhito Tanaka | Nagoya City University | Professor | Genome-wide research for identification of host factors associated with liver disease progression or improvement after hepatitis C virus eradication |
FY2016 | FY2018 | Nobuyuki Enomoto | University of Yamanashi | Professor | Clarifying the role of new anti-HCV therapies in the pathogenesis of liver disease through the next-generation viral sequencing technology and its clinical applications |
FY2016 | FY2018 | Yukihito Ishizaka | National Center for Global Health and Medicine | Director | Differentiation of mesenchymal stem cells to hepatic cells by artifitial transcriptional factors |
FY2016 | FY2018 | Norifumi Kawada | Osaka City University Graduate School of Medicine | Professor of Medicine | Development of therapy for liver cirrhosis based on the regulation of hepatic stellate cell activation |
FY2016 | FY2018 | Shuichi Kaneko | Kanazawa University | Professor | Elucidation of mechanism how hepatocellular carcinoma develops in chronic hepatitis C, and study of the regulation |
FY2016 | FY2018 | Yoshiharu Matsuura | Osaka University | Professor | Basic and clinical research on liver cancer induced by infection with HCV |
FY2016 | FY2018 | Hideki Ohdan | Hiroshima University | Professor | Development of a novel anti-Hepatitis/HCC therapy by reconstructing innate immunity with multi-pluripotent stem cells |
FY2017 | FY2019 | Takahiro Kodama | Osaka University | Assistant Professor | Discovery and characterization of NASH-derived HCC drivers through forward genetic screens and omics |
FY2017 | FY2019 | Itoh Yoshito | Kyoto Prefectural University of Medicine |
Professor | Apg-2 plays an essential role for the progression of nonalcoholic liver diseases; its application for a useful biomarker and for the development of a novel pharmaceutical agents |
FY2017 | FY2019 | Koh Ono | Kyoto University | Associate Professor | Development of novel strategy for the treatment of NAFLD/NASH by the inhibition of miR-33a/b, which are important for cholesterol metabolism |
FY2017 | FY2019 | Michio Nakaya | Kyushu University | Associate Professor | Functional analysis of a fibrosis-stimulating receptor, which is specifically expressed in myofibroblasts, and the development of a novel strategy for targeting the receptor to treat liver fibrosis |
FY2017 | FY2019 | Yukio Nagasaki | University of Tsukuba | Professor | Development of high performance nanomedicines for chronic inflammatoryliver diseaes |
FY2017 | FY2019 | Toshiji Saibara | Kochi Medical School | Professor | Development of pre-emptive medicine for NAFLD using lipidglycome |
FY2017 | FY2019 | Taro Yamashita | Kanazawa University | Associate Professor | Development of a new therapy to normalize the remodeling of liver associated with hepatic fibrosis. |
Program on the Innovative Development and the Application of New Drugs for Hepatitis B
First Year | Final Year | Principal Investigator | Affiliation | Project Title | |
---|---|---|---|---|---|
FY2017 | FY2021 | Yasuhito Tanaka | Nagoya City University | Professor | Drug screening for developing HBV therapeutics and optimization of the hit compounds |
FY2017 | FY2021 | Kyoji Moriya | The University of Tokyo | Professor | Search for drug candidates with novel mechanisms capable of efficient inhibition of hepatitis B virus propagation |
FY2017 | FY2021 | Takaji Wakita | National Institute for Infectious Diseases | Deputy Director-General | Basic research on hepatitis B virus life cycle and anti-viral development |
FY2017 | FY2021 | Kunitada Shimotohno | National Center for Global Medicine and Health | Project Chief | Analysis of HBV life cycle by using sophisticated reporter HBV systems and its application to the development of a new strategy to suppress HBV infection and replication |
FY2017 | FY2021 | Keiji Ueda | Osaka University | Professor | Exploitation of anti-HBV strategies by targeting cellular factors functioning in the HBV life cycle |
FY2017 | FY2021 | Tatsuya Kanto | National Center for Global Health and Medicine | Director General | Establishment of novel therapeutic strategies against HBV - An integrated Immuno-omics approach |
FY2017 | FY2021 | Takashi Fujita | Kyoto University | Professor | Research for HBV therapy development based on the establishment of HBV-sensitive cell and animal models |
FY2017 | FY2021 | Tetsuo Takehara | Osaka University | Professor | Development of molecular pathogenesis and drug discovery using HBV infection models |
FY2017 | FY2021 | Kazuaki Chayama | Hiroshima University | Professor | Hepatitis B virus eradication therapy development using a highly efficient cell culture system and a long term active chronic hepatitis B mouse model |
FY2017 | FY2021 | Shuichi Kaneko | Kanazawa University | Professor | Development of new antiviral therapies for hepatitis B virus |
FY2017 | FY2021 | Masashi Mizokami | National Center for Global Health and Medicine | Project Leader | Comprehensive development of innovative therapeutic methods for complete inactivation of the HBV genome in the liver through application of genome-editing technology in personalized medicine |
Last updated 05/11/18